ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,272.46
0.82%
Dow Jones
39,134.76
0.77%
Gold vs US Dollar
2,364.30
0.14%
Brent Oil
84.965
-0.05%
Bitcoin
64,616.51
-0.32%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Vivos Therapeutics Inc (VVOS)

  7. Vivos Therapeutics Inc (VVOS) News

Vivos Therapeutics (VVOS)

Vivos Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VVOS
DateTimeSourceHeadlineSymbolCompany
14/06/202421:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VVOSVivos Therapeutics Inc
12/06/202412:30GlobeNewswire Inc.Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution AllianceNASDAQ:VVOSVivos Therapeutics Inc
20/05/202418:04GlobeNewswire Inc.Consolidated Water Comments on ISS and Glass Lewis Reports and Urges Stockholders to Vote “FOR” Re-Election of Its Highly Qualified DirectorsNASDAQ:VVOSVivos Therapeutics Inc
17/05/202421:43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VVOSVivos Therapeutics Inc
15/05/202419:54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VVOSVivos Therapeutics Inc
14/05/202421:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VVOSVivos Therapeutics Inc
14/05/202421:05GlobeNewswire Inc.Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational UpdateNASDAQ:VVOSVivos Therapeutics Inc
14/05/202412:30GlobeNewswire Inc.Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference CallNASDAQ:VVOSVivos Therapeutics Inc
09/04/202412:30GlobeNewswire Inc.Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementNASDAQ:VVOSVivos Therapeutics Inc
28/03/202420:05GlobeNewswire Inc.Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational UpdateNASDAQ:VVOSVivos Therapeutics Inc
28/03/202411:30GlobeNewswire Inc.Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference CallNASDAQ:VVOSVivos Therapeutics Inc
15/02/202413:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VVOSVivos Therapeutics Inc
15/02/202413:00GlobeNewswire Inc.Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross ProceedsNASDAQ:VVOSVivos Therapeutics Inc
14/02/202422:42Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VVOSVivos Therapeutics Inc
06/02/202412:30GlobeNewswire Inc.Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth OpportunitiesNASDAQ:VVOSVivos Therapeutics Inc
08/01/202412:30GlobeNewswire Inc.Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSANASDAQ:VVOSVivos Therapeutics Inc
11/12/202312:30GlobeNewswire Inc.Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”NASDAQ:VVOSVivos Therapeutics Inc
04/12/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VVOSVivos Therapeutics Inc
01/12/202321:12Edgar (US Regulatory)Form 424B1 - Prospectus [Rule 424(b)(1)]NASDAQ:VVOSVivos Therapeutics Inc
30/11/202321:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VVOSVivos Therapeutics Inc
30/11/202321:03Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:VVOSVivos Therapeutics Inc
29/11/202312:30GlobeNewswire Inc.Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep ApneaNASDAQ:VVOSVivos Therapeutics Inc
22/11/202321:46Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:VVOSVivos Therapeutics Inc
14/11/202321:05GlobeNewswire Inc.Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational UpdateNASDAQ:VVOSVivos Therapeutics Inc
09/11/202321:30GlobeNewswire Inc.Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference CallNASDAQ:VVOSVivos Therapeutics Inc
03/11/202321:00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VVOSVivos Therapeutics Inc
02/11/202321:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VVOSVivos Therapeutics Inc
02/11/202321:00GlobeNewswire Inc.Vivos Therapeutics Closes $4 Million Private PlacementNASDAQ:VVOSVivos Therapeutics Inc
31/10/202312:00GlobeNewswire Inc.Vivos Therapeutics Announces Pricing of $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:VVOSVivos Therapeutics Inc
27/10/202321:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VVOSVivos Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VVOS

Your Recent History

EU
WDP26
Warehouses de Pauw 2.5% ...
LATK
MBITETH
MessengerBank Investment
NYSE
JZL
Lehman Abs Boeing A1
BIT
UB9FGZ
Unicredit Bank
NASDAQ
FROXMX
Ubs Cio Top Picks Series...
LSE
96DE
Barclays 23
LSE
55GJ
Nat.grd.e 26
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved